These studies suggest a potential role for FASN in apoptosis, cell proliferation and invasion in HER2-overexpressing breast cancer cells and indicate the possibility that agents targeting FASN could be useful for treating breast cancers, especially those in which HER2 is overexpressed. This evidence concerns the gene ERBB2 and breast cancer.